
Karyopharm beats Q2 revenue estimates but reports larger EPS loss, focusing on oncology programs.
Karyopharm Therapeutics reported Q2 revenue of $33.43 million, beating estimates thanks to strong sales of its cancer drug XPOVIO®. However, the company missed EPS expectations with a loss of $2.32 per share and faces financial challenges including n...

